To date, there are no studies examining the feasibility of a combination of CDK4/6 inhibitor palbociclib with an RRM2 inhibitor for treating both ER+ and ER− palbociclib-resistant breast cancers. This evidence concerns the gene CDK4 and breast carcinoma.